Targeting the PEDV 3CL protease for identification of small molecule inhibitors: an insight from virtual screening, ADMET prediction, molecular dynamics, free energy landscape, and binding energy calculations
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Pathak, Rajesh Kumar | - |
dc.contributor.author | Kim, Won-Il | - |
dc.contributor.author | Kim, Jun-Mo | - |
dc.date.accessioned | 2023-09-06T10:40:56Z | - |
dc.date.available | 2023-09-06T10:40:56Z | - |
dc.date.issued | 2023-04 | - |
dc.identifier.issn | 1754-1611 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/67448 | - |
dc.description.abstract | Background: The porcine epidemic diarrhea virus (PEDV) represents a major health issue for piglets worldwide and does significant damage to the pork industry. Thus, new therapeutic approaches are urgently needed to manage PEDV infections. Due to the current lack of a reliable remedy, this present study aims to identify novel compounds that inhibit the 3CL protease of the virus involved in replication and pathogenesis. Results: To identify potent antiviral compounds against the 3CL protease, a virtual screening of natural compounds (n = 97,999) was conducted. The top 10 compounds were selected based on the lowest binding energy and the protein-ligand interaction analyzed. Further, the top five compounds that demonstrated a strong binding affinity were subjected to drug-likeness analysis using the ADMET prediction, which was followed by molecular dynamics simulations (500 ns), free energy landscape, and binding free energy calculations using the MM-PBSA method. Based on these parameters, four putative lead (ZINC38167083, ZINC09517223, ZINC04339983, and ZINC09517238) compounds were identified that represent potentially effective inhibitors of the 3CL protease. Conclusion: Therefore, these can be utilized for the development of novel antiviral drugs against PEDV. However, this requires further validation through in vitro and in vivo studies. © 2023, The Author(s). | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | BioMed Central Ltd | - |
dc.title | Targeting the PEDV 3CL protease for identification of small molecule inhibitors: an insight from virtual screening, ADMET prediction, molecular dynamics, free energy landscape, and binding energy calculations | - |
dc.type | Article | - |
dc.identifier.doi | 10.1186/s13036-023-00342-y | - |
dc.identifier.bibliographicCitation | Journal of Biological Engineering, v.17, no.1 | - |
dc.description.isOpenAccess | Y | - |
dc.identifier.wosid | 000970119700001 | - |
dc.identifier.scopusid | 2-s2.0-85152959602 | - |
dc.citation.number | 1 | - |
dc.citation.title | Journal of Biological Engineering | - |
dc.citation.volume | 17 | - |
dc.type.docType | Article | - |
dc.publisher.location | 영국 | - |
dc.subject.keywordAuthor | MD simulation | - |
dc.subject.keywordAuthor | PEDV | - |
dc.subject.keywordAuthor | Pig | - |
dc.subject.keywordAuthor | Veterinary drug | - |
dc.subject.keywordAuthor | Virtual screening | - |
dc.subject.keywordPlus | PORCINE EPIDEMIC DIARRHEA | - |
dc.subject.keywordPlus | DRUG DISCOVERY | - |
dc.subject.keywordPlus | CORONAVIRUS | - |
dc.subject.keywordPlus | DOCKING | - |
dc.subject.keywordPlus | TOOL | - |
dc.relation.journalResearchArea | Biochemistry & Molecular Biology | - |
dc.relation.journalResearchArea | Biotechnology & Applied Microbiology | - |
dc.relation.journalWebOfScienceCategory | Biochemical Research Methods | - |
dc.relation.journalWebOfScienceCategory | Biotechnology & Applied Microbiology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.